content:zonisamide

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
Next revision		 Previous revision
Next revisionBoth sides next revision
content:zonisamide [2020/02/13 15:53] – [References] icnacontent:zonisamide [2020/02/23 22:55] – [Zonisamide] icna
Line 1: Line 1:
 ====== Zonisamide ====== ====== Zonisamide ======
- +Zonisamide is a synthetic 1,2-benzisoxazole derivative (1,2-benzisoxazole-3-methanesulfonamide). It is chemically classified as a sulfonamide with a structural similarity to serotonin. It was first introduced as an AED in Japan in 1989.
-Efficacy, dose and mean plasma levels were similar in multi-centre studies with Japanese and Caucasian subjects[(:cite:Wroe2009>Wroe SJ. Zonisamide. In: Shorvon S, Perucca E, Engel JJr, eds. The treatment of epilepsy (3nd edition). Oxford: Willey-Blackwell, 2009:713-20.)] [(:cite:Chadwick2002>Chadwick DW, Marson AG. Zonisamide add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2002;2:CD001416.)]. +
 ===== Authorised indications ===== ===== Authorised indications =====
  
Line 29: Line 27:
  
 **Reference range:** 15–40 mg/l (45–180 μmol/l). **Reference range:** 15–40 mg/l (45–180 μmol/l).
 +
 +see [[https://bnfc.nice.org.uk/drug/zonisamide.html|Zonisamide in the British National Formulary]]
  
 ==== Main ADRs ==== ==== Main ADRs ====
Line 76: Line 76:
  
 ==== References ==== ==== References ====
-~~refnotes cite~~+~~REFNOTES~~ 
 +~~AUTHORS~~ 
 +{{tag>pharmacopoeia}}
  • content/zonisamide.txt
  • Last modified: 2022/04/30 18:38
  • by administrator@icnapedia.org